All news

Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash

Bristol Myers Squibb received expanded FDA approval for CAMZYOS to include pediatric patients, impacting its stock which saw a short-term decline but strong year-to-date and past-year gains. The company's stock is currently trading below analyst targets and intrinsic value models, suggesting it is undervalued, particularly as its growth portfolio contributes significantly to overall sales. Investors are advised to consider the company's risks, such as patent expiries and pipeline delays, alongside its growth prospects.

Read original source

BMY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.